Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antiarrhythmic agents: current situation]

D Bonhorst1

  • 1Serviço de Cardiologia do Hospital de Santa Cruz.

Revista Portuguesa De Cardiologia : Orgao Oficial Da Sociedade Portuguesa De Cardiologia = Portuguese Journal of Cardiology : an Official Journal of the Portuguese Society of Cardiology
|May 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ablation of pulmonary vein foci for the treatment of atrial fibrillation; percutaneous electroanatomical guided approach.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2002
Same author

Implantable cardioverter-defibrillator: beyond efficacy.

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology·2002
Same author

[National Pacing Registry -- 1999].

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology·2002
Same author

[National registry of non-invasive electrocardiology in 1999].

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology·2002
Same author

[National electrophysiology registries for the year 2000].

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology·2001
Same author

[Certification in interventional electrophysiology].

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology·2001

The Cardiac Arrhythmia Suppression Trial (CAST) highlighted risks of antiarrhythmic drugs and emphasized placebo controls. Beta-blockers and Class III drugs show promise for treating ventricular arrhythmias post-CAST.

Area of Science:

  • Cardiology
  • Clinical Trials
  • Pharmacology

Context:

  • The Cardiac Arrhythmia Suppression Trial (CAST) significantly influenced cardiology practice.
  • CAST underscored the importance of placebo controls and the dangers of using surrogate endpoints for mortality.
  • The trial led to changes in antiarrhythmic drug prescriptions, labeling, and research focus.

Purpose:

  • To evaluate the impact of the Cardiac Arrhythmia Suppression Trial (CAST) on antiarrhythmic drug therapy.
  • To reassess the
  • To explore alternative treatments for ventricular arrhythmias following CAST findings.

Summary:

  • CAST demonstrated that Class I antiarrhythmic drugs, while suppressing arrhythmias, can increase mortality.
  • Beta-blockers emerged as effective in reducing sudden cardiac death post-myocardial infarction.

Related Experiment Videos

  • Class III drugs, like amiodarone and DL-sotalol, show promise due to their distinct electrophysiological actions.

    • Impact:

    • Reduced reliance on Class I antiarrhythmic drugs for ventricular arrhythmias.
    • Shift towards beta-blockers and Class III drugs in managing cardiac arrhythmias.
    • Emphasis on robust clinical trial design, including placebo controls and mortality endpoints.